Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA377467
Max Phase: Preclinical
Molecular Formula: C18H18Cl2N2O2
Molecular Weight: 365.26
Molecule Type: Small molecule
Associated Items:
ID: ALA377467
Max Phase: Preclinical
Molecular Formula: C18H18Cl2N2O2
Molecular Weight: 365.26
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CC(NC(=O)Nc2cccc(Cl)c2)c2cc(Cl)ccc2O1
Standard InChI: InChI=1S/C18H18Cl2N2O2/c1-18(2)10-15(14-9-12(20)6-7-16(14)24-18)22-17(23)21-13-5-3-4-11(19)8-13/h3-9,15H,10H2,1-2H3,(H2,21,22,23)
Standard InChI Key: YTCPAIDEHJAZKD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 365.26 | Molecular Weight (Monoisotopic): 364.0745 | AlogP: 5.42 | #Rotatable Bonds: 2 |
Polar Surface Area: 50.36 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.20 | CX Basic pKa: | CX LogP: 4.52 | CX LogD: 4.52 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.75 | Np Likeness Score: -1.06 |
1. Sebille S, Gall D, de Tullio P, Florence X, Lebrun P, Pirotte B.. (2006) Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim., 49 (15): [PMID:16854075] [10.1021/jm060161z] |
2. Khelili S, Florence X, Bouhadja M, Abdelaziz S, Mechouch N, Mohamed Y, de Tullio P, Lebrun P, Pirotte B.. (2008) Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators., 16 (11): [PMID:18479927] [10.1016/j.bmc.2008.04.043] |
3. Goffin E, Lamoral-Theys D, Tajeddine N, de Tullio P, Mondin L, Lefranc F, Gailly P, Rogister B, Kiss R, Pirotte B.. (2012) N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis., 54 [PMID:22809560] [10.1016/j.ejmech.2012.06.050] |
Source(1):